卡介苗治疗失败后膀胱癌的临床与临床前治疗
本系统综述评估了卡介苗(BCG)治疗失败后非肌层浸润性膀胱癌的多种保留膀胱治疗方案,共纳入70项研究、73篇报告、27种治疗选择。结果显示膀胱内化疗和热疗联合丝裂霉素C在12和24个月完全缓解率较高,N-803和基因治疗等新型药物显示有前景的结果,但多数试验为单臂非对照队列且患者数量有限。
要点
- 膀胱内化疗及联合化疗12个月完全缓解率为10%-83%,进展率为0%-18%。
- 热疗联合化疗12个月完全缓解率为50%-85%,3级毒性率为0%-15%。
- 新型药物12个月完全缓解率为6%-91%,N-803和基因治疗显示有前景的结果。
核心结论
- 保留膀胱治疗在BCG治疗失败后的非肌层浸润性膀胱癌中取得中等程度的成功。
- 膀胱内化疗和热疗联合丝裂霉素C在12和24个月完全缓解率最高。
- 新型药物中N-803和基因治疗显示有前景的结果,可能作为BCG治疗失败后非肌层浸润性膀胱癌的未来治疗选择。
- 商业可用和不可用的治疗在BCG治疗失败后膀胱癌中均显示低毒性特征。
研究设计与样本
- 系统综述,检索PubMed/Medline、Cochrane Library和Embase,纳入评估BCG治疗失败后复发性非肌层浸润性膀胱癌治疗的临床试验。
- 纳入既往1个或多个疗程BCG治疗失败的患者,排除非英语研究、包含肌层浸润性膀胱癌患者的研究及缺乏治疗后反应评估的研究。
- 共纳入70项研究、73篇报告,评估27种治疗选择,发表于1998年至2021年。
- 未进行正式偏倚风险评估。
主要发现
- 单药膀胱内化疗和多种膀胱内化疗药物联合在12个月完全缓解率为10%-83%。
- 热疗联合化疗的12个月完全缓解率为50%-85%,进展率为0%-18%。
- 免疫治疗药物在中位随访12个月时进展率为7%-22%。
- 新型药物12个月完全缓解率根据治疗不同为6%-91%。
- 3级毒性总发生率:膀胱内化疗及联合化疗为0%-55%,热疗联合化疗为0%-15%,免疫治疗为12%-13%,新型药物为0%-17%。
临床怎么用
- 作者认为,膀胱内化疗和热疗联合丝裂霉素C在12和24个月完全缓解率最高。
- 作者认为,新型药物中N-803和基因治疗显示有前景的结果,可能作为BCG治疗失败后非肌层浸润性膀胱癌的未来治疗选择。
- 本系统综述的综合分析可作为BCG无反应领域治疗决策和临床试验设计的参考。
局限性
- 大多数可用临床试验为单臂非对照队列且患者数量有限,数据的强度和可比性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Intravesical bacillus Calmette-Guérin is the current first-line treatment for high-grade nonmuscle-invasive bladder cancer; however, a substantial proportion of patients are unresponsive to bacillus Calmette-Guérin treatment. While cystectomy is often recommended in bladder cancer following bacillus Calmette-Guérin failure, there are numerous established therapeutic agents and pre-commercialized trials describing treatments for nonmuscle-invasive bladder cancer following failed bacillus Calmette-Guérin treatment. Our objective in this systematic review is to characterize the efficacy of these therapeutic agents by reporting their corresponding complete response rates and toxicity profiles. MATERIALS AND METHODS: We conducted a systematic review of all available clinical trials evaluating therapies to treat recurring nonmuscle-invasive bladder cancer after previous intravesical bacillus Calmette-Guérin. Bacillus Calmette-Guérin failure patients who had previously failed 1 or more courses of prior bacillus Calmette-Guérin therapy were included. Studies that were not in the English language, included muscle-invasive bladder cancer patient populations, or lacked a post-treatment evaluation of response were excluded. We used PubMed/Medline, the Cochrane Library, and Embase to search for relevant studies. No formal risk of bias assessment was conducted. Complete response rates for 3, 6, 12, and 24 months post-treatment evaluation, progression rates, cystectomy rates, and 12 complications are reported. RESULTS: A total of 70 studies with 73 reports evaluating 27 treatment options were retained for final analysis. These treatments were reported in 5 categories including intravesical chemotherapy, combination therapy, hyperthermia paired with intravesical chemotherapy, immunotherapy, and novel agents, with published years ranging from 1998 to 2021. Single intravesical chemotherapy and the combination of multiple intravesical chemotherapy agents demonstrate varied complete response rates of 10%-83% at 12 months. Limited clinical data evaluating hyperthermia paired with chemotherapy demonstrate 12-month complete response rates of 50%-85%. Despite these reported response rates, progression rates ranged from 0%-18%. Moreover, immunotherapeutic agents demonstrate progression rates of 7% to 22% at a median of 12 months of follow-up. Novel agents displayed a wide range of complete response rates (6% to 91%) at 12 months based on the treatment used. Total grade 3 toxicity rates range from 0%-55% for intravesical chemotherapy and combination intravesical chemotherapy agents, 0%-15% for hyperthermia paired with chemotherapy agents, 12%-13% for immunotherapy agents, and 0%-17% for novel agents. CONCLUSIONS: Bladder-preserving treatments accomplish moderate success in nonmuscle-invasive bladder cancer following bacillus Calmette-Guérin failure. As the majority of available clinical trials are single-armed uncontrolled cohorts and contain a limited number of patients, strength and comparability of the data are limited. In general, intravesical chemotherapy and hyperthermia paired with mitomycin C demonstrate some of the highest complete response rates at 12 and 24 months. Similarly, among the pre-commercialized novel agents, N-803 and gene therapy display promising results and may serve as potential future treatment for nonmuscle-invasive bladder cancer following failed bacillus Calmette-Guérin treatment. In terms of toxicity/complication rates, both commercially available and unavailable treatments showcase low toxicity profiles for bladder cancer following bacillus Calmette-Guérin failure. The comprehensive analysis provided by this systematic review can serve as a reference for treatment decisions and clinical trial design in the bacillus Calmette-Guérin-unresponsive domain.
引用
- Nazmifar M, Williams C, Naser-Tavakolian A, et al. Clinical and Preclinical Therapies for Bladder Cancer Following Bacillus Calmette-Guérin Failure. J Urol. 2022. PMID: 36067380. doi:10.1097/JU.0000000000002957
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。